The research, published in the journal Supportive Care in Cancer, compared two ways of administering photobiomodulation therapy, a technique that uses low-level lasers to stimulate tissue healing and reduce inflammation. In the intraoral approach, the laser is applied directly inside the mouth, touching the mucosa at dozens of precisely mapped points. In the extraoral approach, light is delivered from outside the cheek and lips, requiring no mouth opening and no contact with sensitive tissue. A team led by researchers at the Federal University of Paraná and Erasto Gaertner Hospital in Curitiba found that when families experienced both methods, nearly two-thirds preferred the extraoral technique, driven overwhelmingly by one factor: comfort.

The study enrolled pediatric patients aged eighteen or younger who were being treated for leukemia, lymphoma, or osteosarcoma with high-dose methotrexate, a chemotherapy drug strongly associated with mucositis. Because the trial used a crossover design, every child received both forms of photobiomodulation during successive chemotherapy cycles, typically spaced three weeks apart. Treatment began before the methotrexate infusion and continued daily until hospital discharge, with a median of four sessions per cycle. After experiencing both modalities, parents and caregivers completed a structured nine-item questionnaire about their preferences, the discomfort they observed, and their impressions of how well each method controlled pain.

The technical contrast between the two protocols was striking. The intraoral protocol, adapted from guidelines issued by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology, required irradiation at forty-two separate points distributed across the buccal mucosa, the tongue, the floor of the mouth, the lips, and the soft palate. Light delivery alone took roughly seven minutes, with total clinical time stretching from twenty to forty minutes. The extraoral device, by comparison, used eight emitters firing simultaneously, four lateral ones delivering 4.30 joules per square centimeter and four central ones delivering 34.50 joules per square centimeter, across just three anatomical regions: the orbicularis oris muscle and the left and right buccinator muscles. Each region received ten seconds of irradiation, and the entire appointment lasted five to ten minutes.

The results were unambiguous on the question of tolerability. Discomfort during application was reported by 43.8 percent of caregivers for the intraoral method but only 6.3 percent for the extraoral method, a difference that reached statistical significance with a p-value of 0.001 using McNemar’s test for paired comparisons. When asked which modality they preferred, 65.6 percent chose the extraoral approach, citing greater comfort and the advantage of not needing to hold the mouth open. This matters enormously in pediatric oncology, where children may suffer from trismus, pain, or simply limited cooperation during mucositis episodes, making prolonged intraoral procedures difficult or impossible to complete.

Yet the story grew more nuanced when the researchers examined perceptions of pain control. Although families preferred the extraoral device for its comfort, 34.4 percent believed the intraoral method provided better pain relief, compared with only 12.5 percent who favored the extraoral route for analgesia. The authors offer a plausible biophysical explanation: when light must traverse multiple tissue barriers from outside the face, some energy is dissipated before reaching the target tissue, potentially weakening the analgesic effect. Differences in the severity and distribution of mucositis lesions between cycles may also have confounded how caregivers judged pain relief. Notably, however, these subjective impressions did not correspond to measurable differences in the occurrence or severity of oral mucositis between the two modalities.

Indeed, half of the children in the sample developed oral mucositis during follow-up, and no statistically significant association emerged between the preferred modality and mucositis occurrence. The researchers are careful to frame this as exploratory rather than as proof that the two methods are clinically equivalent, given the small sample of thirty-two respondents and a 15.6 percent rate of missing data caused by the inability to link some online questionnaire responses to clinical records. The study was also not prospectively registered, lacked a formal sample-size calculation for the questionnaire component, and relied on retrospective caregiver recall, all of which introduce the possibility of bias, particularly recency effects from the most recent treatment cycle.

What the findings do establish, the authors argue, is that acceptance and tolerability deserve a seat at the table when clinicians choose supportive care protocols. Photobiomodulation is already recommended by international guidelines for preventing oral mucositis in adults receiving head and neck radiotherapy or hematopoietic stem cell transplantation, but pediatric protocols remain fragmented, with no consensus on optimal dosimetric parameters. Because the therapy must be repeated daily across several days of hospitalization, the cumulative burden of an uncomfortable procedure compounds quickly. The extraoral approach also avoids direct contact with ulcerated tissue, which may reduce the risk of opportunistic infections in immunocompromised children and simplifies clinical logistics in busy inpatient units.

The Brazilian results align with a growing international literature. Earlier feasibility studies of extraoral photobiomodulation in pediatric inpatient settings reported successful daily prophylaxis without pain or treatment interruption, and a combined intraoral-extraoral therapeutic protocol achieved success in 77 percent of mucositis episodes with no adverse events. A recent multicenter randomized trial in adults with head and neck cancer found no relevant differences between the two routes in mucositis severity, lesion duration, or functional impairment. In the absence of evidence that one delivery method is clinically superior, one research group has suggested that the best parameter set may simply be the one that is fastest and most comfortable for the patient, a principle the new caregiver data strongly reinforce.

For the roughly 34 percent of families in the study who still preferred the intraoral method, and for the caregivers who perceived it as more effective at controlling pain, the trade-off is not trivial. The authors emphasize that perceived efficacy in their study reflects subjective impressions, not measured clinical outcomes, and they call for larger, prospectively designed trials to settle questions of comparative effectiveness. But their central message is one that resonates far beyond laser dentistry: in pediatric medicine, the treatment a child can tolerate day after day may be the treatment that ultimately works best. When a therapy’s success depends on repeated administration in patients too young, too sick, or too sore to cooperate, comfort is not a luxury. It is a clinical variable, and one that the extraoral laser, in this study at least, decisively won.

Subject of Research: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for preventing oral mucositis in pediatric oncology patients

Article Title: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients

Article References: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients. (n.d.). https://doi.org/10.1007/s00520-026-11227-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11227-3

Keywords: photobiomodulation, oral mucositis, pediatric oncology, low-level laser therapy, chemotherapy side effects, supportive care, high-dose methotrexate, caregiver-reported outcomes, extraoral laser, intraoral laser, treatment tolerability, MASCC/ISOO guidelines

The biological rationale for this call is straightforward once the mechanics of CAR-T therapy are understood. Before engineered T-cells are infused, patients typically receive lymphodepleting chemotherapy, a regimen designed to suppress their existing immune system so that the infused cells can expand without being rejected. This creates a window of profound immunosuppression, often compounded by severe neutropenia, in which the body’s defenses against bacteria, fungi, and viruses are dramatically weakened. At the same time, many candidates for CAR-T have already been through multiple lines of chemotherapy, which damages the oral mucosa, alters saliva production, and disrupts the delicate microbial ecosystem of the mouth. The result is that even a routine dental infection or an untreated cavity can become a serious systemic threat precisely when the patient is most vulnerable.

The oral cavity is, in fact, one of the most microbiologically dense environments in the human body, harboring hundreds of bacterial species alongside fungi such as Candida albicans. When mucosal barriers break down, as they commonly do during intensive cancer therapy, these microorganisms can translocate into the bloodstream. Recent research on Candida has shown how fungal cells can cross the intestinal epithelial barrier, and the same principle applies to oral tissues. In a patient recovering from lymphodepletion and facing the inflammatory storm of cytokine release syndrome, a dental abscess or fungal overgrowth is not a minor inconvenience; it is a potential source of sepsis, treatment delay, or even failure of the CAR-T product itself. Niscola and Del Principe emphasize that oral infectious complications are among the avoidable hazards that a structured dental evaluation could help prevent.

Evidence supporting this concern is accumulating. A retrospective observational study published in the same journal examined oral manifestations and dental management in patients undergoing CAR-T cell therapy and documented a range of problems, including mucositis, infections, and xerostomia, the distressing dryness of the mouth that follows damage to salivary glands. Related work in patients who have undergone allogeneic hematopoietic stem cell transplantation, a closely related form of cellular therapy, has measured long-term changes in the immunological components of saliva, suggesting that glandular function and mucosal immunity may take months or years to recover, if they recover at all. These findings paint a picture of the mouth as a barometer of systemic vulnerability, one that changes measurably during and after aggressive immunotherapy.

The functional consequences extend beyond infection. New clinical data on swallowing outcomes after CAR-T treatment in patients with non-Hodgkin lymphoma have documented dysphagia, or difficulty swallowing, as a real and underappreciated complication of the therapy pathway. Taste disturbances, or dysgeusia, have also been reported in association with immunotherapy, and recent translational work has explored microbiome-aware nutritional strategies to address them. When eating becomes painful, difficult, or unappetizing, patients lose weight, malnutrition sets in, and recovery slows. Oral health, in other words, is not a cosmetic concern but a determinant of whether a patient can maintain the nutritional and physical resilience needed to weather the acute phase of CAR-T therapy and benefit from it in the long run.

Recognizing these risks, the international supportive care community has begun to respond. In 2025, the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology issued a joint clinical practice statement recommending dental evaluation and management before treatment for hematologic malignancies and before CAR-T cell therapy. The statement, authored by an expert panel including Zadik, Raber-Durlacher, Epstein, and colleagues, essentially formalizes what dental oncologists have long practiced: that patients scheduled for intensive immunotherapy should undergo a thorough oral examination, radiographic assessment, and stabilization of active disease before their immune system is deliberately dismantled. Niscola and Del Principe’s commentary can be read as both an endorsement of that guidance and a call to close the gap between recommendation and routine practice.

What would such integration look like in practice? The authors sketch a pathway that begins at patient selection, when a candidate for CAR-T is first identified. At that point, ideally weeks before lymphodepletion begins, a dentist or oral medicine specialist would assess caries risk, screen for periodontal disease and non-vital teeth, evaluate the condition of dentures and oral prostheses, and treat any source of potential infection. Preventive measures would include professional cleaning, fluoride application, and patient education on meticulous oral hygiene. During the hospital admission for infusion, the focus shifts to monitoring for mucositis, managing xerostomia with salivary substitutes or stimulants, and watching for early signs of oral candidiasis or herpes simplex reactivation. After discharge, follow-up dental visits would track healing, address persistent dry mouth or taste changes, and restore function as immune reconstitution proceeds.

The commentary also situates oral care within the broader architecture of CAR-T supportive management, which has grown increasingly sophisticated around toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. Guidelines for managing these systemic toxicities are now well established, and the authors suggest that oral supportive care deserves the same systematic attention. They point to their own prior work on mucosal toxicity in hematological malignancies, which reviewed prevention and management strategies across the spectrum of intensive therapies, as part of a growing literature arguing that the mucosal surfaces of the body are a frontline in cancer supportive care. The mouth, being simultaneously a sensory organ, a digestive gateway, and a microbial reservoir, sits at the intersection of several of these concerns.

There are practical challenges to implementing the vision. CAR-T therapy is delivered in a relatively small number of specialized centers, and patients often travel long distances for treatment, which complicates coordination with community dental providers. Many patients arrive with years of neglected dental care, particularly those whose cancer diagnosis interrupted routine checkups, and complete dental rehabilitation can take longer than the clinical window allows. Prioritization therefore becomes essential: treating active infection and removing unstable teeth take precedence over elective work, and the MASCC/ISOO statement offers a framework for triage. The authors argue that embedding a dental assessment checklist into the standard CAR-T workup, much as cardiac and infectious disease evaluations are already routine, would require modest resources but could prevent disproportionate harm.

Ultimately, the message of the commentary is one of integration rather than novelty. CAR-T cell therapy represents one of the most striking achievements of modern medicine, and its expanding applications across hematological malignancies continue to grow, as recent reviews of the field document. But the technology’s promise can only be realized if patients survive and thrive through the treatment window, and that depends on the unglamorous details of supportive care. Oral health, the authors contend, should no longer be an afterthought delegated to chance. By bringing dentists into the multidisciplinary team that plans and delivers CAR-T therapy, centers can reduce infectious complications, preserve nutrition and quality of life, and give patients the best possible chance of enjoying the remissions that this remarkable therapy can deliver.

Subject of Research: Integrating oral health and preventive dental care into CAR-T cell therapy supportive care

Article Title: Integrating oral health and preventive dental care into CAR-T cell therapy

Article References: Niscola, P., & Del Principe, M. I. (2026). Integrating oral health and preventive dental care into CAR-T cell therapy. Supportive Care in Cancer, 34(10), Article 1012. https://doi.org/10.1007/s00520-026-11268-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11268-8

Keywords: CAR-T cell therapy, oral health, preventive dental care, supportive care, hematologic malignancies, mucositis, immunosuppression, dysgeusia, dysphagia, oral infections, immunotherapy, MASCC/ISOO guidelines